


Cite this: *Chem. Sci.*, 2017, 8, 4006

## Two-photon fluorescent probe for revealing drug-induced hepatotoxicity *via* mapping fluctuation of peroxynitrite†

Yong Li,‡ Xilei Xie,‡ Xiu'e Yang, Mengmeng Li, Xiaoyun Jiao, Yuhui Sun, Xu Wang\* and Bo Tang \*

Drug-induced injury has attracted increasing attention in public health issues. Among them, hepatotoxicity has been regarded as the leading clinical problem caused by drug toxicity. However, owing to the complexity of the involved pathophysiological mechanisms and the lack of noninvasive, straightforward, and real-time tools, drug-induced hepatotoxicity has rarely been predicted satisfactorily. In this paper, by utilizing the reactive species peroxynitrite (ONOO<sup>-</sup>) as a biomarker, we present a two-photon fluorescent probe, TP-KA, holding rapid response, high specificity and sensitivity towards ONOO<sup>-</sup>, to investigate drug (acetaminophen and tolcapone)-related liver injury and the remediate effect of *N*-acetyl cysteine (NAC). With the support of TP-KA, we obtained direct and visual evidence of the upregulation of ONOO<sup>-</sup> during drug challenge both in live cells and mice, which was accompanied by liver tissue injury and tyrosine nitration. These findings demonstrate that ONOO<sup>-</sup> is a good and appropriate biomarker of hepatotoxicity, and nitrosative stress may be necessary for acetaminophen and tolcapone to exert their toxicity. Moreover, TP-KA can be employed as a powerful tool to pre-detect drug-induced organism injury and study the effect of antidotes.

Received 21st January 2017

Accepted 13th March 2017

DOI: 10.1039/c7sc00303j

rsc.li/chemical-science

## Introduction

Drug-induced injury, as a long-term concern, has attracted increasing attention as a public health issue. Moreover, it is cited as the most common reason for an approved drug to be withdrawn from the market, or labelled with a black box warning.<sup>1,2</sup> Attributed to the central role of transforming and clearing exogenous and endogenous xenobiotics from the human body, the liver is often the most susceptible to damage by drugs, which ultimately results in hepatotoxicity being regarded as the leading clinical problem.<sup>3–5</sup> As such, the preclinical investigation of drug-induced hepatotoxicity is required to improve patient safety and therapeutic treatment.

Unfortunately, owing to the complexity of the involved pathophysiological mechanisms, drug-induced hepatotoxicity has rarely been predicted satisfactorily.<sup>6–8</sup> In general, it is reported that the reactive metabolites formed from drugs are responsible for most cases of hepatotoxicity,<sup>9–11</sup> which are

usually accompanied by the generation of reactive small molecules, including reactive oxygen species (ROS) and reactive nitrogen species (RNS).<sup>12,13</sup> Therefore, ROS and RNS might be employed as biomarkers to predict drug-related hepatotoxicity.<sup>8,14</sup> Peroxynitrite (ONOO<sup>-</sup>), a kind of RNS which is generated by the diffusion-limited reaction of superoxide anion radicals (O<sub>2</sub><sup>•-</sup>) with nitric oxide (NO), could be an excellent alternative because of its high oxidative and nitrosative activity towards biomolecules.<sup>15,16</sup> Hence, the efficient tracking of ONOO<sup>-</sup> during drug challenge will add benefits to the in-depth understanding of the hepatotoxicity mechanism. However, the elusive nature of ONOO<sup>-</sup> under physiological conditions,<sup>17</sup> and its properties such as an extremely short half-life (<10 ms), nanomolar homeostasis concentration, and high chemical reactivity, precludes its direct tracking *in situ*. Recently, fluorescence imaging has gained much attention for its outstanding properties in terms of direct visualization and satisfied temporal and spatial resolution,<sup>18–25</sup> and a number of fluorescent probes have been developed for ONOO<sup>-</sup> detection in biological systems.<sup>26–35</sup> Nonetheless, few probes have been utilized to investigate the role ONOO<sup>-</sup> plays in drug-induced hepatotoxicity,<sup>8</sup> especially probes with two-photon excitability since two-photon probes show the advantages of deep tissue penetration, less photodamage, and good resolution.<sup>36–39</sup>

In this work, a new two-photon fluorescent probe, TP-KA, was designed and synthesized for ONOO<sup>-</sup> detection with a rapid response, high specificity, and good sensitivity. By

College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Institute of Molecular and Nano Science, Shandong Normal University, Jinan 250014, P. R. China. E-mail: tangb@sdsu.edu.cn; wangxu@sdsu.edu.cn

† Electronic supplementary information (ESI) available: Detailed experimental procedures, mass spectra, figures, tables and NMR spectra. See DOI: 10.1039/c7sc00303j

‡ These authors contributed equally to this work.








Fig. 3 TPM images of exogenous  $\text{ONOO}^-$  in HepG2 cells. (a) The cells were stained with TP-KA (5.0  $\mu\text{M}$ , 20 min). (b) The cells were exposed to SIN-1 (1.0 mM, 30 min) and then incubated with TP-KA (5.0  $\mu\text{M}$ , 20 min). (c) The cells were exposed to SIN-1 (1.0 mM, 30 min) and then treated with uric acid (100  $\mu\text{M}$ , 3 h), followed by incubation with TP-KA (5.0  $\mu\text{M}$ , 20 min). (d) The relative fluorescence intensity of (a)–(c). The images were obtained with 800 nm excitation and 500–600 nm collection. The values are the mean  $\pm$  s.d. for  $n = 3$ , \*\*\* $p < 0.001$ . Scale bar = 15  $\mu\text{m}$ .



Fig. 4 TPM images of drug-induced injury with HepG2 cells. (a) and (f) The cells were stained with TP-KA (5.0  $\mu\text{M}$ , 20 min). (b) and (c) The cells were exposed to 250 and 500  $\mu\text{M}$  APAP for 1 h, respectively, and then treated with TP-KA (5.0  $\mu\text{M}$ , 20 min). (d) The cells were pretreated with NAC (1.0 mM, 1 h), and then exposed to 500  $\mu\text{M}$  APAP, followed by treatment with TP-KA (5.0  $\mu\text{M}$ , 20 min). (g) and (h) The cells were exposed to 250 and 500  $\mu\text{M}$  tolcapone for 1 h, respectively, and then treated with TP-KA (5.0  $\mu\text{M}$ , 20 min). (i) The cells were pretreated with NAC (1.0 mM, 1 h), and then exposed to 500  $\mu\text{M}$  tolcapone, followed by treatment with TP-KA (5.0  $\mu\text{M}$ , 20 min). (e) The relative fluorescence intensity of (a)–(d). (j) The relative fluorescence intensity of (f)–(i). The images were obtained with 800 nm excitation and 500–600 nm collection. The values are the mean  $\pm$  s.d. for  $n = 3$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . Scale bar = 15  $\mu\text{m}$ .

### Kinetic investigation of TP-KA

The kinetic characteristics of TP-KA were investigated (Fig. S3<sup>†</sup>). In the absence of  $\text{ONOO}^-$ , the constant and weak fluorescence intensity indicated that TP-KA presented a low background signal and was stable towards light irradiation. In the presence of  $\text{ONOO}^-$ , a rapid and drastic fluorescence enhancement was observed within 40 s, and then leveled off, hinting that TP-KA was able to efficiently capture  $\text{ONOO}^-$  in spite of its short lifetime and high activity.

### The specificity of TP-KA towards $\text{ONOO}^-$

The specificity of TP-KA towards  $\text{ONOO}^-$  was examined. Gratifyingly, as illustrated in Fig. 1, no obvious fluorescence intensity change was triggered after the incubation of TP-KA with a number of highly oxidizing ROS or RNS, including  $\text{H}_2\text{O}_2$ ,  $\text{ClO}^-$ ,  $\cdot\text{OH}$ , TBHP,  $\text{O}_2^{\cdot-}$ ,  $^1\text{O}_2$ , and NO. Meanwhile, the fluorescence response of TP-KA towards the reductive reactive species




Fig. 5 TPM images of the liver slices of mice. The mice were injected intraperitoneally with various substances and then with TP-KA (50  $\mu\text{M}$ , 100  $\mu\text{L}$ ) via the tail vein. (a) and (f) PBS buffer only (the control group); (b) and (c) APAP (100  $\text{mg kg}^{-1}$  and 300  $\text{mg kg}^{-1}$ , respectively); (d) NAC (300  $\text{mg kg}^{-1}$ ) pretreatment and then APAP (300  $\text{mg kg}^{-1}$ ); (g) and (h) Tolcapone (100  $\text{mg kg}^{-1}$  and 300  $\text{mg kg}^{-1}$ , respectively); (i) NAC (300  $\text{mg kg}^{-1}$ ) pretreatment and then tolcapone (300  $\text{mg kg}^{-1}$ ); (e) The relative fluorescence intensity of (a)–(d); (j) The relative fluorescence intensity of (f)–(i). The images were obtained with 800 nm excitation and 500–600 nm collection. The values are the mean  $\pm$  s.d. for  $n = 3$ , \* $p < 0.05$ , \*\*\* $p < 0.001$ . Scale bar = 20  $\mu\text{m}$ .



Fig. 6 Representative H&E staining images of the liver of mice treated under various conditions. (a) and (e) PBS buffer only (the control group); (b) and (c) APAP (100  $\text{mg kg}^{-1}$  and 300  $\text{mg kg}^{-1}$ , respectively); (d) NAC (300  $\text{mg kg}^{-1}$ ) pretreatment and then APAP (300  $\text{mg kg}^{-1}$ ); (f) and (g) Tolcapone (100  $\text{mg kg}^{-1}$  and 300  $\text{mg kg}^{-1}$ , respectively); and (h) NAC (300  $\text{mg kg}^{-1}$ ) and then tolcapone (300  $\text{mg kg}^{-1}$ ). Scale bar = 50  $\mu\text{m}$ .

in cells, such as glutathione (GSH), cysteine (Cys), homocysteine (Hcy), hydrogen sulfide ( $\text{H}_2\text{S}$ ), and ascorbic acid (Vc), was also evaluated. Satisfyingly, no significant fluorescence increment was observed. In addition, negligible fluorescence augmentation was induced after the incubation of TP-KA with various cations ( $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Mg}^{2+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Co}^{2+}$ ,  $\text{Cu}^{2+}$ ,  $\text{Zn}^{2+}$ , and  $\text{Fe}^{3+}$ ), anions ( $\text{NO}_2^-$ ,  $\text{NO}_3^-$ ,  $\text{HCO}_3^-$ ,  $\text{CH}_3\text{COO}^-$ ,  $\text{CO}_3^{2-}$ ,  $\text{S}_2\text{O}_3^{2-}$ ,  $\text{SO}_3^{2-}$ ,  $\text{SO}_4^{2-}$ , and  $\text{PO}_4^{3-}$ ), and amino acids (Ser, Pro, Thr, Gly, and Val), which commonly exist in biological systems. Collectively, these results demonstrated the high specificity of TP-KA towards  $\text{ONOO}^-$  over other bioanalytes.

### Fluorescence response of TP-KA towards $\text{ONOO}^-$

On the basis of the excellent specificity of TP-KA to  $\text{ONOO}^-$ , the fluorescence spectral variation of TP-KA in the presence of  $\text{ONOO}^-$  was then investigated to profile its response behavior in detail. As can be seen from Fig. 2, upon incubation with different concentrations (0–10  $\mu\text{M}$ ) of  $\text{ONOO}^-$ , a gradual dose-








Fig. 7 Real-time TPM images of the livers of mice. (a) A surgical procedure was performed to expose the livers for imaging. (b) The mice were injected intraperitoneally with various substances: PBS buffer only for the control group; tolcapone ( $300 \text{ mg kg}^{-1}$ ) for the drug group; uric acid ( $300 \text{ mg kg}^{-1}$ ) pretreatment and then tolcapone ( $300 \text{ mg kg}^{-1}$ ) for the ONOO<sup>-</sup> elimination group; and NAC ( $300 \text{ mg kg}^{-1}$ ) pretreatment and then tolcapone ( $300 \text{ mg kg}^{-1}$ ) for the remedial group. The data were recorded every 5 min. Excitation wavelength: 800 nm. Collection wavelength: 500–600 nm. Scale bar = 50  $\mu\text{M}$ .

dependent fluorescence enhancement was obtained. The fluorescence intensity of TP-KA exhibits an excellent linear relationship ( $R^2 = 0.995$ ) with ONOO<sup>-</sup> concentration with a regression equation of  $F = -9086.50 + 11\,698.06 [\text{ONOO}^-]$  ( $\mu\text{M}$ ). The limit of detection (LOD) was calculated to be as low as 25 nM based on  $3\sigma/k$  (where  $\sigma$  is the standard deviation of 11 blank samples, and  $k$  is the slope of the linear graph), which enabled TP-KA to be sensitive enough for tracing ONOO<sup>-</sup> in the biosystems. Furthermore, the effect of pH was investigated (Fig. S4†). In the absence of ONOO<sup>-</sup>, the fluorescence intensity of TP-KA itself remained unchanged at the wide pH range 5.0–9.0, indicating that TP-KA was hardly influenced by the pH. Meanwhile, upon the addition of ONOO<sup>-</sup>, unchanged and strong fluorescence signals were detected in the pH range 5.0–9.0, which well covered the pH range of physiological environments. Therefore, combined with the results of its outstanding response behavior, TP-KA exhibits robust analytical potential for biological applications.

### The proposed mechanism for the sensing of ONOO<sup>-</sup>

The reaction mechanism of TP-KA with ONOO<sup>-</sup> was further confirmed using high resolution mass spectrometer analysis (Fig. S5†). Upon the incubation of TP-KA with ONOO<sup>-</sup> for 10 min, the reaction mixture was found to have mass peaks at  $m/z = 341.1672$  and  $m/z = 166.0194$ , corresponding to compound 1 and the byproduct 4-nitrobenzoic acid, respectively. Both the spectral variations and the mass analysis results strongly validated the proposed sensing mechanism displayed in Scheme S2.†

### Two-photon fluorescence properties of TP-KA

The two-photon absorption cross-section ( $\delta$ ) of TP-KA and its sensing product 1 were investigated, as  $\delta$  is a critical parameter for a two-photon imaging probe. The  $\delta_{\text{max}}$  values of TP-KA and compound 1 were acquired at 800 nm and were 95 GM (1 GM =

$10^{-50} \text{ m}^4 \text{ s per photon}$ ) and 193 GM, respectively. The higher two-photon absorption cross-section of compound 1 over TP-KA could be attributed to its electron donating moiety, the 4-amino group. Moreover, the high  $\delta_{\text{max}}$  value enabled TP-KA to be applied in two-photon fluorescence microscopy imaging.

### Visualizing exogenous ONOO<sup>-</sup> in live cells

Encouraged by the notable response properties of TP-KA, the feasibility of it mapping the ONOO<sup>-</sup> level in biological systems was assessed with a two-photon excitation microscopy (TPM) system. Prior to cell imaging, an MTT assay was performed to identify the cytotoxicity of TP-KA, and the results (Fig. S6†) implied that TP-KA presented excellent biocompatibility ( $\text{IC}_{50} = 63 \mu\text{M}$ ). Then, utilizing SIN-1 as the ONOO<sup>-</sup> donor, exogenous ONOO<sup>-</sup> imaging was performed in HepG2 cells. As displayed in Fig. 3, in the control group, a negligible fluorescence signal was observed in the cells loaded with TP-KA. Contrastingly, a significant enhancement of the intracellular fluorescence intensity was obtained upon SIN-1 exposure, which was efficiently stopped by uric acid, an ONOO<sup>-</sup> scavenger. Furthermore, the bright field images displayed intact cells, implying the good viability of the cells throughout the experiment. Consequently, the data confirmed that TP-KA showed promise to act as a mapping tool to explore ONOO<sup>-</sup> fluctuations under biological conditions.

### Imaging drug-induced hepatotoxicity and the remediation effect of NAC

Normally, hepatotoxicity corresponds to chemical-driven liver damage.<sup>44</sup> It is well-known that an overdose of acetaminophen (APAP), a common household medication used to treat pain and fever, could induce hepatotoxicity related to the overproduction of ROS and RNS.<sup>45</sup> Therefore, by guiding with the imaging biomarker ONOO<sup>-</sup>, APAP-induced damage was visualized in cells, with the aid of TP-KA. As presented in Fig. 4a–e, after the treatment of APAP, a notably stronger fluorescence signal in HepG2 cells was detected than that observed under normal conditions. Therefore, the results revealed that intracellular ONOO<sup>-</sup> was upregulated under the administration of APAP, thus contributing to oxidative and nitrosative stress injury. Furthermore, as can be seen in the figure, the strong fluorescence intensity could be effectively attenuated by *N*-acetyl cysteine (NAC), which remediated cell injury *via* the depletion of the ROS and RNS levels by increasing the GSH level and binding with the toxic products of APAP.<sup>46,47</sup> Therefore, the results indicated that TP-KA exhibited excellent properties for visualizing the cell damage induced by APAP and NAC displayed a good antidotal effect.

Then, the cell injury of another drug, tolcapone, was explored. Tolcapone was used initially for the treatment of Parkinson's disease, but it was withdrawn from the market in the EU and labelled with a black box warning in the US because of its severe hepatotoxicity.<sup>48,49</sup> No clear mechanism has been proposed regarding tolcapone-induced liver toxicity yet. But it has been hypothesized that it is associated with dysfunctional mitochondrial respiration due to the uncoupling of oxidative



phosphorylation.<sup>50</sup> Accordingly, using **TP-KA**, injury due to tolcapone in cells was mapped to explore the possible injury mechanism (Fig. 4f–j). As can be seen in the figure, the HepG2 cells that were exposed to tolcapone demonstrated brighter, dose-dependent fluorescence compared to the control group, suggesting the upregulation of the ONOO<sup>−</sup> level. This means that, as well as APAP, tolcapone could also induce HepG2 cell damage *via* the overproduction of ONOO<sup>−</sup> through the induction of oxidative and nitrosative stress. Meanwhile, the apparent decrease in the fluorescence intensity of cells treated with NAC before the tolcapone treatment implied the remedial role of NAC in tolcapone-induced cell damage.

Subsequently, the hepatotoxicity of APAP and tolcapone was visualized in tissues to strongly verify the toxicity mechanism. Generally, Kunming mice were divided into three groups. For the control group, the mice were administered an intraperitoneal injection of PBS buffer before being given a tail-vein injection of **TP-KA**. The second group was given an intraperitoneal injection of PBS buffer solution containing various concentrations of APAP or tolcapone, and then a tail-vein injection of **TP-KA** 30 min later. The mice in the last group were pretreated with an intraperitoneal injection of NAC 1 h before drug administration. Then all of the mice were anesthetized and dissected to isolate their livers, which were cut into slices for TPM fluorescence imaging. As shown in Fig. 5, weak fluorescence intensity was obtained in the mice liver tissue of the control group, implying a low ONOO<sup>−</sup> level under normal conditions. In contrast, after the administration of either APAP or tolcapone, the mice liver tissue of the second group emitted obvious fluorescence, indicating up-regulated ONOO<sup>−</sup> after drug treatment. Meanwhile, for the mice pretreated with NAC before drug administration, negligible fluorescence signal change was observed in both the APAP and tolcapone group, confirming the protective effect of NAC in the liver. These results verified that both APAP and tolcapone could induce hepatotoxicity *via* the upregulation of ONOO<sup>−</sup>.

Next, the histological and immunohistochemical analysis on the liver tissues were carried out to identify the histological changes during the drug administration. Nitrotyrosine was employed as the immunohistochemical biomarker to confirm the nitrosative stress of ONOO<sup>−</sup> to protein tyrosine residues.<sup>51</sup> Briefly, Kunming mice liver sections were prepared from the three groups that were processed under various conditions, including PBS buffer only, drug administration, and NAC pretreatment. As can be seen in Fig. 6 and S7,† both the histological changes (*i.e.*, cellular shrinkage or blebbing, the rupture of the cell membrane, and the condensation of chromatin) and nitrotyrosine formation could be obviously observed after the administration of the two drugs, implying that the liver injury happened because of the drug metabolism. However, the mice in the NAC pretreatment group displayed no distinct changes in the histological and immunohistochemical analysis, indicating that the liver injury could be effectively suppressed by NAC. Taken together, these results were in good agreement with the observation of *in vitro* fluorescence imaging using ONOO<sup>−</sup> as a biomarker (Fig. 4 and 5).

Finally, tolcapone-induced hepatotoxicity and NAC remediation were monitored *in vivo* through a real-time method. As can be seen from Fig. 7, after tolcapone administration, the fluorescence intensities of the mice livers displayed gradual increments in a time-dependent manner. In particular, the observable fluorescence intensity augmentation at 15 min indicated that ONOO<sup>−</sup>-related stress began to show up after drug administration in such a short time. In addition, the clearance assay was also performed using uric acid to confirm the overproduction of ONOO<sup>−</sup> after tolcapone administration. Moreover, with the passage of time, no obvious intensity augmentation was observed in the NAC pretreatment group, indicating effective NAC remediation after the drug treatment. It should be noted that for the first time, the early warning potential of ONOO<sup>−</sup> for tolcapone-induced hepatotoxicity was revealed and demonstrated explicitly using **TP-KA**.

## Conclusions

In conclusion, we have constructed a new two-photon fluorescent probe, **TP-KA**, for ONOO<sup>−</sup> detection. Using the excellent properties of **TP-KA**, ONOO<sup>−</sup> as a biomarker for APAP- and tolcapone-induced hepatotoxicity was exploited. It was found that an apparent ONOO<sup>−</sup> level upregulation occurred during the drug-induced liver damage, and *N*-acetyl cysteine (NAC) might serve as a superior alternative antidote against the toxic metabolism of the drugs. In particular, the early warning potential of ONOO<sup>−</sup> for tolcapone-induced hepatotoxicity was revealed. Therefore, we anticipate that **TP-KA** may be employed as a powerful tool to pre-detect drug-induced organism injury and study the effect of antidotes.

## Acknowledgements

This work was supported by the 973 Program (2013CB933800) and National Natural Science Foundation of China (21390411, 21535004, 21375080, and 21505088). Male Kunming mice (20g) were purchased from the School of Medicine at Shandong University. All of the animal experiments were in agreement with the guidelines of the Institutional Animal Care and Use Committee.

## References

- 1 A. Nasr, T. J. Lauterio and M. W. Davis, *Adv. Ther.*, 2011, **28**, 842–856.
- 2 M. Chen, V. Vijay, Q. Shi, Z. Liu, H. Fang and W. Tong, *Drug Discovery Today*, 2011, **16**, 697–703.
- 3 N. Kaplowitz, *Clin. Infect. Dis.*, 2004, **38**, S44–S48.
- 4 A. M. Larson, J. Polson, R. J. Fontana, T. J. Davern, E. Lalani, L. S. Hynan, J. S. Reisch, F. V. Schiødt, G. Ostapowicz and A. O. Shakil, *Hepatology*, 2005, **42**, 1364–1372.
- 5 P. B. Watkins and L. B. Seeff, *Hepatology*, 2006, **43**, 618–631.
- 6 M. P. Holt and C. Ju, *AAPS J.*, 2006, **8**, E48–E54.
- 7 D. M. Bissell, G. J. Gores, D. L. Laskin and J. H. Hoofnagle, *Hepatology*, 2001, **33**, 1009–1013.



- 8 A. J. Shuhendler, K. Pu, L. Cui, J. P. Uetrecht and J. Rao, *Nat. Biotechnol.*, 2014, **32**, 373–380.
- 9 D. J. Antoine, D. P. Williams and B. K. Park, *Expert Opin. Drug Metab. Toxicol.*, 2008, **4**, 1415–1427.
- 10 J. L. Walgren, M. D. Mitchell and D. C. Thompson, *Crit. Rev. Toxicol.*, 2005, **35**, 325–361.
- 11 B. K. Park, N. R. Kitteringham, J. L. Maggs, M. Pirmohamed and D. P. Williams, *Annu. Rev. Pharmacol.*, 2005, **45**, 177–202.
- 12 S. Russmann, G. A. Kullak-Ublick and I. Grattagliano, *Curr. Med. Chem.*, 2009, **16**, 3041–3053.
- 13 D. Pessayre, A. Mansouri, D. Haouzi and B. Fromenty, *Cell Biol. Toxicol.*, 1999, **15**, 367–373.
- 14 H. Jaeschke, G. J. Gores, A. I. Cederbaum, J. A. Hinson, D. Pessayre and J. J. Lemasters, *Toxicol. Sci.*, 2002, **65**, 166–176.
- 15 P. Pacher, J. S. Beckman and L. Liaudet, *Physiol. Rev.*, 2007, **87**, 315–424.
- 16 C. Szabó, H. Ischiropoulos and R. Radi, *Nat. Rev. Drug Discovery*, 2007, **6**, 662–680.
- 17 G. Ferrer-Sueta and R. Radi, *ACS Chem. Biol.*, 2009, **4**, 161–177.
- 18 J. Zheng, R. Yang, M. Shi, C. Wu, X. Fang, Y. Li, J. Li and W. Tan, *Chem. Soc. Rev.*, 2015, **44**, 3036–3055.
- 19 A. T. Aron, M. O. Loehr, J. Bogena and C. J. Chang, *J. Am. Chem. Soc.*, 2016, **138**, 14338–14346.
- 20 Y. Li, X. Wang, J. Yang, X. Xie, M. Li, J. Niu, L. Tong and B. Tang, *Anal. Chem.*, 2016, **88**, 11154–11159.
- 21 W. Shi, X. Li and H. Ma, *Angew. Chem., Int. Ed.*, 2012, **124**, 6538–6541.
- 22 X. Wang, J. Sun, W. Zhang, X. Ma, J. Lv and B. Tang, *Chem. Sci.*, 2013, **4**, 2551–2556.
- 23 K. Xu, D. Luan, X. Wang, B. Hu, X. Liu, F. Kong and B. Tang, *Angew. Chem., Int. Ed.*, 2016, **128**, 12943–12946.
- 24 M. H. Lee, N. Park, C. Yi, J. H. Han, J. H. Hong, K. P. Kim, D. H. Kang, J. L. Sessler, C. Kang and J. S. Kim, *J. Am. Chem. Soc.*, 2014, **136**, 14136–14142.
- 25 X. Wang, J. Lv, X. Yao, Y. Li, F. Huang, M. Li, J. Yang, X. Ruan and B. Tang, *Chem. Commun.*, 2014, **50**, 15439–15442.
- 26 J. Miao, Y. Huo, Q. Liu, Z. Li, H. Shi, Y. Shi and W. Guo, *Biomaterials*, 2016, **107**, 33–43.
- 27 K. Xu, H. Chen, J. Tian, B. Ding, Y. Xie, M. Qiang and B. Tang, *Chem. Commun.*, 2011, **47**, 9468–9470.
- 28 X. Li, R. R. Tao, L. J. Hong, J. Cheng, Q. Jiang, Y. M. Lu, M. H. Liao, W. F. Ye, N. N. Lu and F. Han, *J. Am. Chem. Soc.*, 2015, **137**, 12296–12303.
- 29 X. Zhou, Y. Kwon, G. Kim, J.-H. Ryu and J. Yoon, *Biosens. Bioelectron.*, 2015, **64**, 285–291.
- 30 T. Peng, N. K. Wong, X. Chen, Y. K. Chan, D. H. H. Ho, Z. Sun, J. J. Hu, J. Shen, H. El-Nezami and D. Yang, *J. Am. Chem. Soc.*, 2014, **136**, 11728–11734.
- 31 T. Ueno, Y. Urano, H. Kojima and T. Nagano, *J. Am. Chem. Soc.*, 2006, **128**, 10640–10641.
- 32 F. Yu, P. Li, G. Li, G. Zhao, T. Chu and K. Han, *J. Am. Chem. Soc.*, 2011, **133**, 11030–11033.
- 33 X. Jia, Q. Chen, Y. Yang, Y. Tang, R. Wang, Y. Xu, W. Zhu and X. Qian, *J. Am. Chem. Soc.*, 2016, **138**, 10778–10781.
- 34 D. Cheng, Y. Pan, L. Wang, Z. B. Zeng, L. Yuan, X. B. Zhang and Y. T. Chang, *J. Am. Chem. Soc.*, 2017, 285–292.
- 35 Z. Song, D. Mao, S. H. Sung, R. T. Kwok, J. W. Lam, D. Kong, D. Ding and B. Z. Tang, *Adv. Mater.*, 2016, **28**, 7249–7256.
- 36 W. Denk, J. H. Strickler and W. W. Webb, *Science*, 1990, **248**, 73–76.
- 37 K. H. Wang, A. Majewska, J. Schummers, B. Farley, C. Hu, M. Sur and S. Tonegawa, *Cell*, 2006, **126**, 389–402.
- 38 W. Zhang, P. Li, F. Yang, X. Hu, C. Sun, W. Zhang, D. Chen and B. Tang, *J. Am. Chem. Soc.*, 2013, **135**, 14956–14959.
- 39 Y. Tang, X. Kong, A. Xu, B. Dong and W. Lin, *Angew. Chem., Int. Ed.*, 2016, **55**, 3356–3359.
- 40 X. Xie, X. Yang, T. Wu, Y. Li, M. Li, Q. Tan, X. Wang and B. Tang, *Anal. Chem.*, 2016, **88**, 8019–8025.
- 41 A. Sikora, J. Zielonka, M. Lopez, J. Joseph and B. Kalyanaraman, *Free Radical Biol. Med.*, 2009, **47**, 1401–1407.
- 42 P. Jin, C. Jiao, Z. Guo, Y. He, S. Zhu, H. Tian and W. Zhu, *Chem. Sci.*, 2014, **5**, 4012–4016.
- 43 S. Wei, Y. Sun, C. Tan, S. Yan, P. Guo, X. Hu and J. Fan, *Luminescence*, 2013, **28**, 318–326.
- 44 W. M. Lee, *N. Engl. J. Med.*, 2003, **349**, 474–485.
- 45 K. Du, A. Ramachandran and H. Jaeschke, *Redox Biol.*, 2016, **10**, 148–156.
- 46 C. L. Tsai, W. T. Chang, T. I. Weng, C. C. Fang and P. D. Watson, *Clin. Ther.*, 2005, **27**, 336–341.
- 47 K. R. Atkuri, J. J. Mantovani, L. A. Herzenberg and L. A. Herzenberg, *Curr. Opin. Pharmacol.*, 2007, **7**, 355–359.
- 48 N. Borges, *Drug Saf.*, 2003, **26**, 743–747.
- 49 C. W. Olanow, *Arch. Neurol.*, 2000, **57**, 263–267.
- 50 D. D. Truong, *Clin. Interventions Aging*, 2009, **4**, 109–113.
- 51 A. H. Cross, P. T. Manning, M. K. Stern and T. P. Misko, *J. Neuroimmunol.*, 1997, **80**, 121–130.

